Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Frazzoni

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Alimentary Pharmacology & Therapeutics|January 5, 2011
Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitisM Frazzoni, R Conigliaro, G Melotti
Gut|February 1, 1984
Jejunal intraepithelial lymphocytes in coeliac disease: are they increased or decreased?G R Corazza, M Frazzoni, G Gasbarrini
Alimentary Pharmacology & Therapeutics|December 5, 2003
Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux diseaseM Frazzoni, E De Micheli, V Savarino
Alimentary Pharmacology & Therapeutics|May 5, 2011
Reflux parameters as modified by EsophyX or laparoscopic fundoplication in refractory GERDM Frazzoni, R Conigliaro, R Manta, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 24, 2007
Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitorsM Frazzoni, M Manno, E De Micheli, et al.
Neurogastroenterology and Motility|October 13, 2011
The added value of quantitative analysis of on-therapy impedance-pH parameters in distinguishing refractory non-erosive reflux disease from functional heartburnM Frazzoni, R Conigliaro, V G Mirante, et al.
Alimentary Pharmacology & Therapeutics|February 22, 2002
Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparisonM Frazzoni, E De Micheli, A Grisendi, et al.
Alimentary Pharmacology & Therapeutics|April 23, 2002
Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppressionM Frazzoni, E De Micheli, A Grisendi, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2003
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazoleM Frazzoni, E De Micheli, A Grisendi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 18, 2005
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazoleM Frazzoni, M Manno, E De Micheli, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Alimentary Pharmacology & Therapeutics|January 5, 2011
Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitisM Frazzoni, R Conigliaro, G Melotti
Gut|February 1, 1984
Jejunal intraepithelial lymphocytes in coeliac disease: are they increased or decreased?G R Corazza, M Frazzoni, G Gasbarrini
Alimentary Pharmacology & Therapeutics|December 5, 2003
Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux diseaseM Frazzoni, E De Micheli, V Savarino
Alimentary Pharmacology & Therapeutics|May 5, 2011
Reflux parameters as modified by EsophyX or laparoscopic fundoplication in refractory GERDM Frazzoni, R Conigliaro, R Manta, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 24, 2007
Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitorsM Frazzoni, M Manno, E De Micheli, et al.
Neurogastroenterology and Motility|October 13, 2011
The added value of quantitative analysis of on-therapy impedance-pH parameters in distinguishing refractory non-erosive reflux disease from functional heartburnM Frazzoni, R Conigliaro, V G Mirante, et al.
Alimentary Pharmacology & Therapeutics|February 22, 2002
Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparisonM Frazzoni, E De Micheli, A Grisendi, et al.
Alimentary Pharmacology & Therapeutics|April 23, 2002
Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppressionM Frazzoni, E De Micheli, A Grisendi, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2003
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazoleM Frazzoni, E De Micheli, A Grisendi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 18, 2005
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazoleM Frazzoni, M Manno, E De Micheli, et al.
Pageof 4